ORIC Pharmaceuticals announced the selection of the Phase 3 dose for rinzimetostat, a prostate cancer drug, and plans to start the Himalayas-1 global registrational trial in the first half of 2026. Early data show rinzimetostat has a strong safety profile and promising efficacy compared to current treatments for metastatic castration-resistant prostate cancer (mCRPC). The company also reported progress with enozertinib for lung cancer and expects multiple clinical updates later in 2026. With $420 million in cash, ORIC is well-funded to support operations into late 2028 and aims to become a multi-asset oncology company.
Polaris Inc. reported a strong quarterly performance with earnings per share of $1.97, beating estimates by over 155%, and revenues of $2.02 billion, up 9.2% year-over-year. The growth was driven by sales recovery in the utility off-road vehicle segm...
Seagate Technology is set to report its Q2 2026 earnings with analysts expecting an EPS of $5.10 and revenue around $3.5 billion, reflecting strong demand for data storage driven by AI growth. The company's optimistic guidance aligns with these estim...
Teladoc Health, a leader in virtual healthcare services, has seen its average analyst price target rise from $8.35 to $11.00, reflecting increased confidence in its market position. The stock recently jumped 6.1% with high trading volume, driven by r...
Procter & Gamble, a leading consumer goods company and Dividend King, is seeing a decline in analyst price targets from $162.52 to $152 over the past year, though Deutsche Bank remains optimistic with a $177 target. Despite a strong history of beatin...
Cognizant Technology Solutions has seen a decline in analyst price targets from $74.94 to $56.33 over the past year, reflecting increased caution about its stock performance. Despite this, some analysts remain optimistic, with a notable price target ...
